Artificial intelligence is transitioning from a buzzword to a core consideration in nearly every private equity deal, but particularly in healthcare. The challenge now is not whether Al matters but how to translate its potential into proven outcomes. Graham Defries, partner in Goodwin's life sciences group, agrees: "Al in healthcare is top of mind for most private equity investors. The critical question is: how big is the opportunity? We're entering the first generation of Al-discovered or Al-optimized drugs in later-stage clinical trials. In the next year or two, we will see real-world data to determine if these drugs have higher success rates in Phase Il trials compared to those developed through traditional methods. Al can significantly reduce these costs by designing safer molecules, identifying the patient populations most likely to benefit from treatment, and screening out those that are less likely to respond." Read the Real Deals article for more.